Do analysts prefer AVTE or ENTX?

Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 211.42%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, AVTE or ENTX?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Entera Bio N/A N/A -$11.44M -$0.35 N/A

Is AVTE or ENTX more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Entera Bio N/A -147.19% -103.22%

Which has preferable earnings and valuation, ENTX or MPLT?

Entera Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.35 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is ENTX or MPLT more profitable?

Maplight Therapeutics' return on equity of -118.06% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Maplight Therapeutics N/A -118.06% -59.67%

Does the media prefer ENTX or MPLT?

In the previous week, Entera Bio and Entera Bio both had 8 articles in the media. Maplight Therapeutics' average media sentiment score of 0.80 beat Entera Bio's score of 0.20 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ENTX or TECX?

Entera Bio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.35 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A

Is ENTX or TECX more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Tectonic Therapeutic N/A -35.26% -33.59%

Does the media refer more to ENTX or TECX?

In the previous week, Entera Bio and Entera Bio both had 8 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.31 beat Entera Bio's score of 0.20 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ENTX or NGNE more profitable?

Neurogene's return on equity of -45.10% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Neurogene N/A -45.10% -41.00%

Does the media favor ENTX or NGNE?

In the previous week, Neurogene had 13 more articles in the media than Entera Bio. MarketBeat recorded 21 mentions for Neurogene and 8 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.20 beat Neurogene's score of -0.15 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurogene 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ZURA or ENTX?

Entera Bio is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A Entera Bio N/A N/A -$11.44M -$0.35 N/A

Is ZURA or ENTX more profitable?

Zura Bio's return on equity of -56.13% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -56.13% -50.15% Entera Bio N/A -147.19% -103.22%

Does the media refer more to ZURA or ENTX?

In the previous week, Entera Bio had 4 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Entera Bio and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Entera Bio's score of 0.20 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Entera Bio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Entera Bio (ENTX) Competitors

$2.89 +0.02 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.05 (+1.90%)

As of 07:34 PM Eastern

Compare

ENTX vs. AVTE, MPLT, TECX, NGNE, and ZURA

Should you buy Entera Bio stock or one of its competitors? Entera Bio's main competitors and comparable companies include Aerovate Therapeutics (AVTE), Maplight Therapeutics (MPLT), Tectonic Therapeutic (TECX), Neurogene (NGNE), and Zura Bio (ZURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entera Bio compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A

In the previous week, Entera Bio had 8 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 8 mentions for Entera Bio and 0 mentions for Aerovate Therapeutics. Entera Bio's average media sentiment score of 0.20 beat Aerovate Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Entera Bio	Neutral

Aerovate Therapeutics' return on equity of -90.19% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Entera Bio	N/A	-147.19%	-103.22%

14.1% of Entera Bio shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 211.42%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts clearly believe Entera Bio is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Entera Bio beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Maplight Therapeutics?

Entera Bio (NASDAQ:ENTX) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Maplight Therapeutics' return on equity of -118.06% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Maplight Therapeutics	N/A	-118.06%	-59.67%

Entera Bio presently has a consensus price target of $9.00, suggesting a potential upside of 211.42%. Maplight Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 152.48%. Given Entera Bio's higher probable upside, research analysts clearly believe Entera Bio is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Entera Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

14.1% of Entera Bio shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Entera Bio and Entera Bio both had 8 articles in the media. Maplight Therapeutics' average media sentiment score of 0.80 beat Entera Bio's score of 0.20 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maplight Therapeutics beats Entera Bio on 7 of the 12 factors compared between the two stocks.

How does Entera Bio compare to Tectonic Therapeutic?

Entera Bio (NASDAQ:ENTX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Tectonic Therapeutic's return on equity of -35.26% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Entera Bio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Entera Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 211.42%. Tectonic Therapeutic has a consensus target price of $77.80, suggesting a potential upside of 122.86%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

In the previous week, Entera Bio and Entera Bio both had 8 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.31 beat Entera Bio's score of 0.20 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tectonic Therapeutic beats Entera Bio on 10 of the 13 factors compared between the two stocks.

How does Entera Bio compare to Neurogene?

Entera Bio (NASDAQ:ENTX) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Entera Bio has higher earnings, but lower revenue than Neurogene. Entera Bio is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A
Neurogene	$930K	777.59	-$90.35M	-$5.03	N/A

Entera Bio presently has a consensus price target of $9.00, suggesting a potential upside of 211.42%. Neurogene has a consensus price target of $83.67, suggesting a potential upside of 131.51%. Given Entera Bio's higher probable upside, research analysts plainly believe Entera Bio is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Neurogene had 13 more articles in the media than Entera Bio. MarketBeat recorded 21 mentions for Neurogene and 8 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.20 beat Neurogene's score of -0.15 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Entera Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Neurogene's return on equity of -45.10% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Neurogene	N/A	-45.10%	-41.00%

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 10.6% of Entera Bio shares are held by insiders. Comparatively, 11.7% of Neurogene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Neurogene beats Entera Bio on 11 of the 15 factors compared between the two stocks.

How does Entera Bio compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Entera Bio is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A

Zura Bio presently has a consensus price target of $14.00, indicating a potential upside of 151.35%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 211.42%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zura Bio's return on equity of -56.13% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-56.13%	-50.15%
Entera Bio	N/A	-147.19%	-103.22%

Zura Bio has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Comparatively, 10.6% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Entera Bio had 4 more articles in the media than Zura Bio. MarketBeat recorded 8 mentions for Entera Bio and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Entera Bio's score of 0.20 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Entera Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zura Bio beats Entera Bio on 9 of the 14 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$496.92M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-8.26	10.67	269.06	25.28
Price / Sales	N/A	1,294.08	602.43	91.76
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	72.25	16.78	12.91	6.24
Net Income	-$11.44M	-$13.32M	$3.45B	$347.60M
7 Day Performance	0.70%	1.74%	1.12%	1.07%
1 Month Performance	78.40%	1.60%	1.79%	1.03%
1 Year Performance	46.70%	56.43%	67.69%	20.77%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.2505 of 5 stars	$2.89 +0.7%	$9.00 +211.4%	+47.9%	$496.92M	N/A	N/A	20	Earnings Report Short Interest Increase
AVTE Aerovate Therapeutics	N/A	$19.15 -3.0%	N/A	+214.1%	$555.06M	N/A	N/A	20	High Trading Volume
MPLT Maplight Therapeutics	4.1398 of 5 stars	$12.94 +3.1%	$34.42 +166.0%	N/A	$551.50M	N/A	N/A	109	Earnings Report Analyst Forecast
TECX Tectonic Therapeutic	2.984 of 5 stars	$29.17 +4.5%	$79.40 +172.2%	+53.8%	$550.44M	N/A	N/A	120
NGNE Neurogene	2.0309 of 5 stars	$34.41 +4.7%	$84.83 +146.5%	+68.8%	$543.68M	$930K	N/A	90	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. AVTE, MPLT, TECX, NGNE, and ZURA

How does Entera Bio compare to Aerovate Therapeutics?

Summary

How does Entera Bio compare to Maplight Therapeutics?

Summary

How does Entera Bio compare to Tectonic Therapeutic?

Summary

How does Entera Bio compare to Neurogene?

Summary

How does Entera Bio compare to Zura Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. AVTE, MPLT, TECX, NGNE, and ZURA

How does Entera Bio compare to Aerovate Therapeutics?

Which has preferable valuation & earnings, AVTE or ENTX?

Does the media prefer AVTE or ENTX?

Is AVTE or ENTX more profitable?

Do insiders & institutionals have more ownership in AVTE or ENTX?

Which has more volatility and risk, AVTE or ENTX?

Do analysts prefer AVTE or ENTX?

Summary

How does Entera Bio compare to Maplight Therapeutics?

Is ENTX or MPLT more profitable?

Do analysts prefer ENTX or MPLT?

Which has preferable earnings and valuation, ENTX or MPLT?

Do insiders and institutionals have more ownership in ENTX or MPLT?

Does the media prefer ENTX or MPLT?

Summary

How does Entera Bio compare to Tectonic Therapeutic?

Is ENTX or TECX more profitable?

Which has stronger valuation and earnings, ENTX or TECX?

Do insiders & institutionals have more ownership in ENTX or TECX?

Which has more risk and volatility, ENTX or TECX?

Do analysts prefer ENTX or TECX?

Does the media refer more to ENTX or TECX?

Summary

How does Entera Bio compare to Neurogene?

Which has stronger valuation and earnings, ENTX or NGNE?

Do analysts recommend ENTX or NGNE?

Does the media favor ENTX or NGNE?

Which has more volatility & risk, ENTX or NGNE?

Is ENTX or NGNE more profitable?

Do institutionals and insiders hold more shares of ENTX or NGNE?

Summary

How does Entera Bio compare to Zura Bio?

Which has preferable earnings & valuation, ZURA or ENTX?

Do analysts prefer ZURA or ENTX?

Is ZURA or ENTX more profitable?

Which has more risk and volatility, ZURA or ENTX?

Do insiders & institutionals hold more shares of ZURA or ENTX?

Does the media refer more to ZURA or ENTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools